PTN - PALATIN TECHNOLOGIES INC

22.445
-0.515   -2.294%

Share volume: 19,496
Last Updated: 03-10-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$22.96
-0.52
-0.02%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
22%
Profitability 28%
Dept financing 23%
Liquidity 47%
Performance 9%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.40%
1 Month
36.11%
3 Months
-9.02%
6 Months
123.33%
1 Year
2,830.16%
2 Year
1,212.57%
Key data
Stock price
$22.44
P/E Ratio 
0.00
DAY RANGE
$21.00 - $23.32
EPS 
$1.44
52 WEEK RANGE
$0.39 - $31.00
52 WEEK CHANGE
$2,804.00
MARKET CAP 
26.187 M
YIELD 
N/A
SHARES OUTSTANDING 
1.772 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.63
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$17,961
AVERAGE 30 VOLUME 
$19,692
Company detail
CEO: Carl Spana
Region: US
Website: palatin.com
Employees: 30
IPO year: 1997
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Palatin Technologies, Inc. develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the. treatment of premenopausal women with hypoactive sexual desire disorder.

Recent news